vs
Esperion Therapeutics, Inc.（ESPR）与INTERNATIONAL BANCSHARES CORP（IBOC）财务数据对比。点击上方公司名可切换其他公司
INTERNATIONAL BANCSHARES CORP的季度营收约是Esperion Therapeutics, Inc.的1.3倍（$217.7M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 4.5%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 2.8%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
国际银行股份公司（International Bancshares Corporation）是总部位于美国得克萨斯州拉雷多的银行控股公司，核心子公司为国际商业银行。目前集团通过旗下银行子公司运营217个营业网点、315台自动柜员机，服务覆盖得克萨斯州、俄克拉荷马州的88个城镇社区。
ESPR vs IBOC — 直观对比
营收规模更大
IBOC
是对方的1.3倍
$168.4M
营收增速更快
ESPR
高出139.2%
4.5%
两年增速更快
ESPR
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $217.7M |
| 净利润 | — | $106.9M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 62.8% |
| 净利率 | — | 62.3% |
| 营收同比 | 143.7% | 4.5% |
| 净利润同比 | — | -7.1% |
| 每股收益（稀释后） | $0.32 | $1.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRIBOC
| Q4 25 | $168.4M | $217.7M | ||
| Q3 25 | $87.3M | $218.1M | ||
| Q2 25 | $82.4M | $208.2M | ||
| Q1 25 | $65.0M | $198.2M | ||
| Q4 24 | $69.1M | $208.3M | ||
| Q3 24 | $51.6M | $211.8M | ||
| Q2 24 | $73.8M | $207.8M | ||
| Q1 24 | $137.7M | $205.8M |
净利润ESPRIBOC
| Q4 25 | — | $106.9M | ||
| Q3 25 | $-31.3M | $108.4M | ||
| Q2 25 | $-12.7M | $100.1M | ||
| Q1 25 | $-40.5M | $96.9M | ||
| Q4 24 | — | $115.1M | ||
| Q3 24 | $-29.5M | $99.8M | ||
| Q2 24 | $-61.9M | $97.0M | ||
| Q1 24 | $61.0M | $97.3M |
营业利润率ESPRIBOC
| Q4 25 | 50.6% | 62.8% | ||
| Q3 25 | -11.4% | 62.6% | ||
| Q2 25 | 8.6% | 60.5% | ||
| Q1 25 | -34.0% | 61.1% | ||
| Q4 24 | -6.4% | 64.2% | ||
| Q3 24 | -31.0% | 60.0% | ||
| Q2 24 | 3.5% | 60.1% | ||
| Q1 24 | 52.5% | 59.9% |
净利率ESPRIBOC
| Q4 25 | — | 62.3% | ||
| Q3 25 | -35.9% | 49.7% | ||
| Q2 25 | -15.4% | 48.1% | ||
| Q1 25 | -62.2% | 48.9% | ||
| Q4 24 | — | 71.5% | ||
| Q3 24 | -57.2% | 47.1% | ||
| Q2 24 | -83.9% | 46.7% | ||
| Q1 24 | 44.3% | 47.3% |
每股收益（稀释后）ESPRIBOC
| Q4 25 | $0.32 | $1.71 | ||
| Q3 25 | $-0.16 | $1.74 | ||
| Q2 25 | $-0.06 | $1.61 | ||
| Q1 25 | $-0.21 | $1.56 | ||
| Q4 24 | $-0.14 | $1.85 | ||
| Q3 24 | $-0.15 | $1.60 | ||
| Q2 24 | $-0.33 | $1.56 | ||
| Q1 24 | $0.34 | $1.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $5.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $3.3B |
| 总资产 | $465.9M | $16.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRIBOC
| Q4 25 | $167.9M | $5.5B | ||
| Q3 25 | $92.4M | $5.6B | ||
| Q2 25 | $86.1M | $5.8B | ||
| Q1 25 | $114.6M | $5.6B | ||
| Q4 24 | $144.8M | $5.4B | ||
| Q3 24 | $144.7M | $5.8B | ||
| Q2 24 | $189.3M | $5.7B | ||
| Q1 24 | $226.6M | $5.7B |
股东权益ESPRIBOC
| Q4 25 | $-302.0M | $3.3B | ||
| Q3 25 | $-451.4M | $3.1B | ||
| Q2 25 | $-433.5M | $3.0B | ||
| Q1 25 | $-426.2M | $2.9B | ||
| Q4 24 | $-388.7M | $2.8B | ||
| Q3 24 | $-370.2M | $2.7B | ||
| Q2 24 | $-344.2M | $2.6B | ||
| Q1 24 | $-294.3M | $2.5B |
总资产ESPRIBOC
| Q4 25 | $465.9M | $16.6B | ||
| Q3 25 | $364.0M | $16.6B | ||
| Q2 25 | $347.1M | $16.5B | ||
| Q1 25 | $324.0M | $16.3B | ||
| Q4 24 | $343.8M | $15.7B | ||
| Q3 24 | $314.1M | $15.9B | ||
| Q2 24 | $352.3M | $15.5B | ||
| Q1 24 | $373.1M | $15.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $491.1M |
| 自由现金流经营现金流 - 资本支出 | — | $472.9M |
| 自由现金流率自由现金流/营收 | — | 217.2% |
| 资本支出强度资本支出/营收 | 0.0% | 8.3% |
| 现金转化率经营现金流/净利润 | — | 4.59× |
| 过去12个月自由现金流最近4个季度 | — | $809.9M |
8季度趋势，按日历期对齐
经营现金流ESPRIBOC
| Q4 25 | $45.2M | $491.1M | ||
| Q3 25 | $-4.3M | $115.2M | ||
| Q2 25 | $-31.4M | $95.5M | ||
| Q1 25 | $-22.6M | $140.5M | ||
| Q4 24 | $-35.0M | $473.9M | ||
| Q3 24 | $-35.3M | $116.5M | ||
| Q2 24 | $-7.2M | $107.2M | ||
| Q1 24 | $53.8M | $135.4M |
自由现金流ESPRIBOC
| Q4 25 | — | $472.9M | ||
| Q3 25 | — | $112.2M | ||
| Q2 25 | — | $91.6M | ||
| Q1 25 | — | $133.1M | ||
| Q4 24 | — | $459.8M | ||
| Q3 24 | $-35.5M | $109.6M | ||
| Q2 24 | $-7.3M | $104.9M | ||
| Q1 24 | $53.8M | $128.9M |
自由现金流率ESPRIBOC
| Q4 25 | — | 217.2% | ||
| Q3 25 | — | 51.5% | ||
| Q2 25 | — | 44.0% | ||
| Q1 25 | — | 67.1% | ||
| Q4 24 | — | 220.8% | ||
| Q3 24 | -68.7% | 51.7% | ||
| Q2 24 | -9.9% | 50.5% | ||
| Q1 24 | 39.0% | 62.6% |
资本支出强度ESPRIBOC
| Q4 25 | 0.0% | 8.3% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 3.7% | ||
| Q4 24 | 0.0% | 6.8% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | 0.1% | 3.2% |
现金转化率ESPRIBOC
| Q4 25 | — | 4.59× | ||
| Q3 25 | — | 1.06× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 4.12× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | 0.88× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IBOC
暂无分部数据
